STOCK TITAN
  1. Home
  2. Sec-filings
  3. CODX
  4. [Form 4] Co-Diagnostics, Inc. Insider Trading Activity

CODX Form 4 shows director stock from RSU vesting, 271,666 shares held

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Co-Diagnostics, Inc. (CODX) reported an equity award-related transaction by a director on 11/23/2025. The reporting person acquired 57,499 shares of common stock at a price of $0.00, reflecting the vesting and settlement of previously granted restricted stock units under the company’s 2015 Long Term Incentive Plan.

After this transaction, the director beneficially owned 271,666 shares of common stock directly and 170,834 restricted stock units. These units come from awards of 40,000, 70,000, 110,000 and 125,000 restricted stock units granted between January 17, 2023 and August 13, 2025, each vesting in six equal installments every six months starting on their respective commencement dates.

Positive

  • None.

Negative

  • None.
Insider SERBIN RICHARD S
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Unit 57,499 $0.00 --
Grant/Award Common Stock 57,499 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 170,834 shares (Direct); Common Stock — 271,666 shares (Direct)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SERBIN RICHARD S
(Last) (First) (Middle)
2401 S. FOOTHILL DRIVE SUITE D
(Street)
SALT LAKE CITY UT 84109
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Co-Diagnostics, Inc. [ CODX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/23/2025 A 57,499(1) A $0.00 271,666 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0.00 11/23/2025 M 57,499 (1) (1) Common Stock 228,333 $0.00 170,834 D
Explanation of Responses:
1. Included in 40,000 restricted stock units awarded to the Reporting Person on January 17, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on May 23, 2023. Included in 70,000 restricted stock units awarded to the Reporting Person on June 12, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2023. Included in 110,000 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2024. Included in 125,000 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in six equal installments every six months commencing on November 23, 2025.
Remarks:
/s/ Richard Serbin 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the CODX director report on this Form 4?

The director reported the acquisition of 57,499 shares of Co-Diagnostics common stock on 11/23/2025, received at a price of $0.00 upon vesting of restricted stock units.

How many Co-Diagnostics (CODX) shares does the director own after this transaction?

Following the reported transaction, the director beneficially owned 271,666 shares of Co-Diagnostics common stock directly.

How many restricted stock units (RSUs) does the CODX director still hold?

After the transaction, the director held 170,834 restricted stock units tied to Co-Diagnostics common stock.

What is the source of the CODX director’s restricted stock units?

The restricted stock units were granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan in awards of 40,000, 70,000, 110,000 and 125,000 units between 2023 and 2025.

How do the CODX restricted stock units vest for this director?

Each award of restricted stock units vests in six equal installments every six months, starting from its respective commencement date, such as May 23, 2023 and November 23, 2023.

What type of relationship does the reporting person have with Co-Diagnostics (CODX)?

The reporting person is identified as a director of Co-Diagnostics, Inc.